Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

BACKGROUND: The current standard of care for pancreatic cancer is weekly gemcitabine administered for 3 of 4 weeks with a 1-week break between treatment cycles. Maximum tolerated dose (MTD)-driven regimens as such are often associated with toxicities. Recent studies demonstrated that frequent dosing...

Descripción completa

Detalles Bibliográficos
Autores principales: Cham, K K Y, Baker, J H E, Takhar, K S, Flexman, J A, Wong, M Q, Owen, D A, Yung, A, Kozlowski, P, Reinsberg, S A, Chu, E M, Chang, C-W A, Buczkowski, A K, Chung, S W, Scudamore, C H, Minchinton, A I, Yapp, D T T, Ng, S S W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905290/
https://www.ncbi.nlm.nih.gov/pubmed/20531411
http://dx.doi.org/10.1038/sj.bjc.6605727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905290/
https://www.ncbi.nlm.nih.gov/pubmed/20531411
http://dx.doi.org/10.1038/sj.bjc.6605727

Ejemplares similares